Utility of ultrasensitive, US Food and Drug Administration–approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas
American Journal of Clinical Pathology · 04.06.2026 · 165 (6)
DOI: 10.1093/ajcp/aqag043 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 05.06.2026. Verfasst von Mohamed Eltahir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States. Hauptthemen laut MEDLINE: Hodgkin Disease, In Situ Hybridization, Immunoglobulin kappa-Chains, Immunoglobulin lambda-Chains. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objectives
Determination of B-cell clonality in formalin-fixed, paraffin-embedded tissues is challenging, especially in cases where tumor B cells are sparse. Flow cytometry is of limited utility in Hodgkin lymphomas, at least in part due to the rarity and fragility of the malignant cells.
Methods
We used a recently US Food and Drug Administration–approved, ultrasensitive κ and λ dual in situ hybridization assay (K/L dual ISH; Roche/Ventana Medical Systems) to evaluate B-cell clonality in 184 classic Hodgkin lymphomas (CHLs) and 113 nodular lymphocyte-predominant Hodgkin lymphomas (NLPHLs).
Results
Five CHLs and 11 NLPHLs were not scorable due to preanalytical variables. Of the 179 scorable CHL cases, none showed light chain messenger RNA expression in the Hodgkin/Reed-Sternberg cells, whereas 89% of NLPHLs (91/102) exhibited light chain expression in lymphocyte-predominant (LP) cells. Among NLPHLs, 66% (68/102) showed κ restriction, 20% (21/102) showed λ restriction, and 1.9% (2/102) showed dual κ and λ expression in the LP cells. There was no appreciable light chain expression in 10% (11/102) of cases.
Conclusions
Although morphology and immunohistochemistry are usually sufficient to separate CHL from NLPHL, determining light chain restriction by K/L dual ISH could provide a valuable adjunct in challenging cases, potentially improving diagnostic accuracy and patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
ORCID-Profile: Oscar Silva, Yasodha Natkunam
Zitieren
APA
Eltahir, M., Young, K., Younes, S., Zhao, S., Silva, O., & Natkunam, Y. (2026). Utility of ultrasensitive, US Food and Drug Administration–approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas. American Journal of Clinical Pathology, 165(6). https://doi.org/10.1093/ajcp/aqag043
Vancouver
Eltahir M, Young K, Younes S, Zhao S, Silva O, Natkunam Y. Utility of ultrasensitive, US Food and Drug Administration–approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas. American Journal of Clinical Pathology. 2026;165(6). doi:10.1093/ajcp/aqag043
BibTeX
@article{Eltahir2026,
author = {Eltahir, Mohamed and Young, Kelly and Younes, Sheren and Zhao, Shuchun and Silva, Oscar and Natkunam, Yasodha},
title = {Utility of ultrasensitive, US Food and Drug Administration–approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {165},
number = {6},
doi = {10.1093/ajcp/aqag043}
}
EUVIMED